Interesting ImagesRole of 68Ga–Prostate-Specific Membrane Antigen PET/CT in Disease Assessment in Glioblastoma Within 48 Hours of SurgeryGupta, Manoj DRM, FEBNM*; Choudhury, Partha Sarathi DNB*; Premsagar, Ishwar Chandra MCH†; Gairola, Munish MD‡; Ahlawat, Parveen DNB‡Author Information From the Departments of *Nuclear Medicine †Neuro & Spine Oncology Services ‡Radiotherapy, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Received for publication April 23, 2019; revision accepted October 12, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Manoj Gupta, DRM, FEBNM, Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi, India 110085. E-mail: email@example.com. Online date: January 30, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p 204-205 doi: 10.1097/RLU.0000000000002893 Buy Metrics Abstract Within 48 hours after surgery, disease assessment in glioblastoma is a challenge for both the clinician and the radiologist. Certain technical and logistical issues prevail in this period. 68Ga–prostate-specific membrane antigen PET/CT is a known molecular imaging marker in prostate cancer. Its role in high-grade gliomas has been recently discussed. We present a case of a 39-year-old man with recurrence glioblastoma of the right frontal lobe and underwent resurgery. After surgery, 68Ga–prostate-specific membrane antigen PET/CT showed residual disease along the posterior and inferior margin of the postoperative cavity. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.